If validated, these findings may be valuable for predicting and preventing engraftment failure in IBD patients following the allo-HSCT, particularly for those with deficiency in XIAP and FOXP3. We are interested in further investigating the precise biological mechanism and the clinical impact of these microbiota using new technologies. The gene discussed is FOXP3; the disease is inflammatory bowel disease.